ENVB - CIK 0000890821
Enveric Biosciences, Inc. trades as ENVB. This page tracks Enveric Biosciences, Inc. through 1,004 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Enveric Biosciences, Inc.'s revenue grew from $6.14M to $39.91M, a compound annual growth rate of 45.4%. Net profit margin expanded from -7.7% to -6.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-15 |
| Major company event | 8-K | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| D | - | 2026-05-04 |
| Major company event | 8-K | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| EFFECT | - | 2026-04-29 |
| 424B3 | - | 2026-04-29 |
The largest companies sharing Enveric Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).
Yes. Enveric Biosciences, Inc. reported net income of $12.10M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.